
Namibia ALMA Quarterly Report Quarter Two, 2023



Scorecard for Accountability and Action



| Commodities Financed | _ | |
|---|-----|---------|
| IRS financing 2023 (% of at-risk population) | | 60 |
| Public sector RDT financing 2023 projection (% of need) | | 100 |
| Public sector ACT financing 2023 projection (% of need) | | 100 |
| Policy | | |
| Signed, ratified and deposited the AMA instrument at the AUC | | |
| Malaria activities targeting refugees in Malaria Strategic Plan | | |
| Malaria activities targeting IDPs in Malaria Strategic Plan | | |
| Zero Malaria Starts With Me Launched | | |
| End Malaria Council and Fund Launched | | |
| Resistance Monitoring, Implementation and Impact | _ | |
| Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO | | |
| Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010 | | 2 |
| Insecticide resistance monitored since 2015 and data reported to WHO | | |
| National Insecticide Resistance Monitoring and Management Plan | | |
| RDTs in stock (>6 months stock) | | |
| ACTs in stock (>6 months stock) | | |
| LLIN/IRS campaign on track | | |
| IRS Operational Coverage (%) | | 64 |
| On track to reduce case incidence by ≥40% by 2021 (vs 2015) | | |
| On track to reduce case mortality by ≥40% by 2021 (vs 2015) | | |
| Tracer Indicators for Maternal and Child Health, NTDs an | d C | ovid 19 |
| Scale of Implementation of iCCM | | |
| Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021) | | |
| Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2022) | | 70 |
| Vitamin A Coverage 2021 (2 doses) | | 59 |
| DPT3 coverage 2022 (vaccination among 0-11 month | | 84 |

Key

Malaria transmission is confined to the north-east part of Namibia where malaria is endemic and about 72% of the population of the country is at risk. The annual reported number of malaria cases in 2021 was 13,738 with 14 deaths.



Target achieved or on track Progress but more effort required Not on track No data Not applicable



Malaria

Progress

The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard, Namibia secured sufficient funding for the required number of ACTs and RDTs for 2023. The country has reported the insecticide resistance data to WHO. Namibia has recently launched the Zero Malaria Starts with Me campaign.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, Namibia has enhanced the tracking and accountability mechanisms for malaria with the development of the Malaria Elimination Scorecard, however this is not yet shared to the ALMA Scorecard Hub. The country has established End Malaria Councils at sub-national level but not yet established the End Malaria and NTD council at national level.

Impact

The annual reported number of malaria cases in 2021 was 13,738 with 14 deaths.

Key Challenges

- Maintaining malaria high on the political and funding agenda.
- There is a need to strengthen cross border collaboration with neighbouring countries.

Previous Key Recommended Actions

Namibia has responded positively to the recommended action on addressing the lack of data on iCCM and continues to strengthen access to treatment of malaria, pneumonia and diarrhoea.

RMNCAH and **NTDs**

Progress

Namibia has enhanced tracking and accountability mechanisms with the development of their Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard.

Progress in addressing Neglected Tropical Diseases (NTDs) in Namibia is shown using a composite index calculated from preventive chemotherapy coverage achieved for schistosomiasis and soil transmitted helminths. In 2021, preventive chemotherapy coverage in Namibia was 0% for the two diseases. Overall, the NTD preventive chemotherapy coverage index for Namibia in 2021 is 0, with no change compared with the 2020 index value of 0.

| Objective | Action Item | Suggested completion timeframe | Progress | Comments - key activities/accomplishments since last quarterly report |
|-----------|---|--------------------------------------|----------|---|
| NTDs | Recognising the negative impact of COVID-19 on the 2021 MDA coverage, ensure that NTD interventions including MDA for schistosomiasis and soil transmitted helminths are implemented | Q4 2023 | | Deliverable not yet due |

Previous Key Recommended Action

| | NEV | nev | Nev | Nev | ney | ney | ney |
|--|-----|-----|-----|-----|-----|-----|-----|

Action achieved Some progress No progress Deliverable not yet due